Image_1_Systematic Analysis of Expression Profiles and Prognostic Significance for FAM83 Family in Non-small-Cell Lung Cancer.TIF
Lung cancer remains a common malignancy and the leading cause of cancer-related deaths in the world. Although dramatic progress made in multimodal therapies, it still has a poor prognosis. The Family with sequence similarity 83 (FAM83) of poorly characterized proteins are defined by the presence of the conserved DUF1669 domain of unknown function at their N-termini, most of which significantly elevated levels of expression in multiple cancers. However, the expression and prognostic values of different FAM83 family in lung cancer, especially in non-small-cell lung cancer (NSCLC), have not been clarified.
MethodsONCOMINE, UALCAN, GEPIA, Kaplan–Meier Plotter, cBioPortal, and STRING databases were utilized in this study.
ResultsThe transcriptional levels of FAM83A/B/C/D/F/G/H were up-regulated in patients with NSCLC. A noticeable correlation was found between the over-expressions of FAM83A/B/D/F/H and clinical cancer stages in NSCLC patients. Besides, higher mRNA expressions of FAM83A/B/C/D/F/H were discovered to be expressively associated with overall survival (OS) in lung cancer patients, furthermore, FAM83A, FAM83C, and FAM83H in OS group achieved 0.9475/1, 0.971897/1, and 0.9454545/0.8974359 specificity/sensitivity in distinguishing short survivors from long survivors, respectively. Moreover, a high mutation rate of FAM83 family (51%) was also observed in lung adenocarcinoma (LUAD) patients, and genetic alteration in the FAM83 family was associated with shorter OS and disease-free survival (DFS) in LUAD patients.
ConclusionOur results indicated that FAM83A/H might play important roles in NSCLC tumorigenesis and might be risk factor for the survival of NSCLC patients.
History
References
- https://doi.org//10.1200/jco.2005.10.462
- https://doi.org//10.18632/oncotarget.9544
- https://doi.org//10.1042/bst20160277
- https://doi.org//10.3390/cancers11050605
- https://doi.org//10.3322/caac.21492
- https://doi.org//10.1038/nature11412
- https://doi.org//10.1158/2159-8290.cd-12-0095
- https://doi.org//10.1016/j.neo.2017.05.002
- https://doi.org//10.3349/ymj.2019.60.7.611
- https://doi.org//10.1172/jci60517
- https://doi.org//10.1158/1541-7786.mcr-13-0289
- https://doi.org//10.1126/scisignal.aao2341
- https://doi.org//10.3389/fonc.2020.00134
- https://doi.org//10.1126/scisignal.2004088
- https://doi.org//10.1172/jci64412
- https://doi.org//10.1371/journal.pone.0010312
- https://doi.org//10.1093/nar/gkn923
- https://doi.org//10.1038/nprot.2008.211
- https://doi.org//10.3390/ijms19041259
- https://doi.org//10.1172/jci60498
- https://doi.org//10.18632/oncotarget.4432
- https://doi.org//10.1016/j.biopha.2019.109780
- https://doi.org//10.1007/s13277-015-4760-9
- https://doi.org//10.1016/j.biopha.2017.03.073
- https://doi.org//10.3892/ijo.2015.2817
- https://doi.org//10.1158/0008-5472.can-11-1403
- https://doi.org//10.1007/s10555-016-9618-0
- https://doi.org//10.1016/s1476-5586(04)80047-2
- https://doi.org//10.1101/gr.132662.111
- https://doi.org//10.7150/jca.20086
- https://doi.org//10.1002/1878-0261.12016
- https://doi.org//10.2147/cmar.s203082
- https://doi.org//10.1007/s10555-015-9562-4
- https://doi.org//10.21037/tlcr.2019.11.04
- https://doi.org//10.1007/s13402-020-00494-9
- https://doi.org//10.1089/dna.2019.4970
- https://doi.org//10.1111/jcmm.14360
- https://doi.org//10.3389/fonc.2020.00180
- https://doi.org//10.18632/aging.102163